abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG
BRIGHT MINDS BIOSCIENCES
BRIGHT MINDS BIOSCIENCES INC.
BRIGHT MINDS BIOSCIENCES drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
- Status
- Public
- HQ
- 19 Vestry St, New York, NY 10013, US
- Employees
- 12
- Programs
- 1063
- Drugs
- 444
- Patents
- 57
BRIGHT MINDS BIOSCIENCES pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BRIGHT MINDS BIOSCIENCES drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
alogliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Glutamate [NMDA] receptor antagonist.
- Mechanism
- Glutamate [NMDA] receptor antagonist
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
US regulatory status: approved.
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
anamorelin
Various (V03)Various (V03) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Ghrelin receptor agonist.
- Mechanism
- Ghrelin receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
apomorphine
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: D2-like dopamine receptor agonist.
- Mechanism
- D2-like dopamine receptor agonist
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor agonist
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: C55-isoprenyl pyrophosphate.
- Target
- C55-isoprenyl pyrophosphate
- Mechanism
- C55-isoprenyl pyrophosphate inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
bedaquiline
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in BRIGHT MINDS BIOSCIENCES's portfolio.
-
US regulatory status: approved. Molecular target: ATP synthase.
- Target
- ATP synthase
- Mechanism
- ATP synthase inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
besilesomab
Various (V09)Various (V09) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase.
- Target
- DNA polymerase
- Mechanism
- DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.
- Target
- 5-hydroxytryptamine receptor 1A
- Mechanism
- Serotonin 1a (5-HT1a) receptor partial agonist
-
caffeine
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
caffeine citrate
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
capsaicin
Nervous system (N01)US regulatory status: approved. Molecular target: Transient receptor potential cation channel subfamily V member 1.
- Target
- Transient receptor potential cation channel subfamily V member 1
- Mechanism
- Vanilloid receptor opener
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cariprazine
Nervous system (N05)Nervous system (N05) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Dopamine D3 receptor modulator.
- Mechanism
- Dopamine D3 receptor modulator
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor modulator
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
cefepime
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in BRIGHT MINDS BIOSCIENCES's portfolio.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
cidofovir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
cinacalcet
Systemic hormonal preparations (H05)Systemic hormonal preparations (H05) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Calcium sensing receptor positive allosteric modulator.
- Mechanism
- Calcium sensing receptor positive allosteric modulator
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Alanine racemase.
- Target
- Alanine racemase
- Mechanism
- Alanine racemase inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
deferiprone
Various (V03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
delamanid
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Molecular target: Mycobacterium tuberculosis H37Rv.
- Target
- Mycobacterium tuberculosis H37Rv
- Mechanism
- Mycobacterium tuberculosis H37Rv inhibitor
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
diflunisal
Nervous system (N02)US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BRIGHT MINDS BIOSCIENCES's portfolio.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Aldehyde dehydrogenase, mitochondrial.
- Target
- Aldehyde dehydrogenase, mitochondrial
- Mechanism
- Aldehyde dehydrogenase inhibitor
-
US regulatory status: approved. Molecular target: Succinate-semialdehyde dehydrogenase, mitochondrial.
- Target
- Succinate-semialdehyde dehydrogenase, mitochondrial
- Mechanism
- Succinate semialdehyde dehydrogenase inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dodecafluoropentane
Various (V08)Various (V08) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
dofetilide
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Voltage-gated inwardly rectifying potassium channel KCNH2.
- Target
- Voltage-gated inwardly rectifying potassium channel KCNH2
- Mechanism
- HERG blocker
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor alpha-1 antagonist
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor agonist
-
US regulatory status: approved.
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
entacapone
Nervous system (N04)US regulatory status: approved. Molecular target: Catechol O-methyltransferase.
- Target
- Catechol O-methyltransferase
- Mechanism
- Catechol O-methyltransferase inhibitor
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
evolocumab
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.
- Target
- Proprotein convertase subtilisin/kexin type 9
- Mechanism
- Subtilisin/kexin type 9 inhibitor
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: RNA-directed RNA polymerase.
- Target
- RNA-directed RNA polymerase
- Mechanism
- RNA-directed RNA polymerase inhibitor
-
fenfluramine
Nervous system (N03)US regulatory status: approved. Mechanism: Serotonin 2c (5-HT2c) receptor agonist.
- Mechanism
- Serotonin 2c (5-HT2c) receptor agonist
-
fentanyl
Nervous system (N02)US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
ferumoxytol
Blood and blood forming organs (B03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
florbetapir (18f)
Various (V09)Various (V09) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
flortaucipir (18f)
Various (V09)Various (V09) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel allosteric antagonist
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
fondaparinux sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.
- Target
- 5-hydroxytryptamine receptor 1A
- Mechanism
- Serotonin 1a (5-HT1a) receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
Development asset linked to BRIGHT MINDS BIOSCIENCES in public FDA and regional records.
-
guanfacine
Cardiovascular system (C02)Cardiovascular system (C02) compound in BRIGHT MINDS BIOSCIENCES's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
guselkumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor